Genmab A/S (FRA:GE9)
272.50
0.00 (0.00%)
At close: Nov 28, 2025
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
€1,222,553
Profits / Employee
€503,327
Market Cap
16.85B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Dec 31, 2020 | 781 | 233 | 42.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
Genmab News
- 4 days ago - Genmab (GMAB) Q3 2025 Earnings Call Transcript - The Motley Fool
- 5 days ago - Artisan International Small-Mid Fund Q3 2025 Performance Review - Seeking Alpha
- 7 days ago - Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami - GlobeNewsWire
- 9 days ago - Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire
- 12 days ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 12 days ago - FDA Greenlights AbbVie And Genmab's EPKINLY Combo For Relapsed Or Refractory Follicular Lymphoma - Nasdaq
- 13 days ago - Genmab Secures FDA Approval Of EPKINLY Combination Therapy For R/R Follicular Lymphoma - Nasdaq